[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545916":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":50,"locations":59,"responsibleParty":86,"collaborators":89,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":102,"sex":108,"minAge":109,"maxAge":25,"enrollmentInfo":110,"targetDuration":25,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":25,"overallStatus":61,"whyStopped":25,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"Xinqiao Hospital of Chongqing","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Endovascular thrombectomy","EXPERIMENTAL","Patients in this group will be treated with medical management plus endovascular thrombectomy",[13,14],"Drug: Medical management","Procedure: Endovascular thrombectomy",{"label":16,"type":17,"description":18,"interventionNames":19},"Medical management","ACTIVE_COMPARATOR","Patients in this group will be treated with medical management alone",[13],[21,26],{"type":22,"name":16,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Medical management includes IV thrombolysis, antiplatelet, and\u002For anticoagulation.",[9,16],null,{"type":27,"name":9,"description":28,"armGroupLabels":29,"otherNames":25},"PROCEDURE","Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and\u002For stenting.",[9],[31,35,38,41,44,47],{"name":32,"affiliation":33,"role":34},"Guangxiong Yuan","Xiangtan Central Hospital","PRINCIPAL_INVESTIGATOR",{"name":36,"affiliation":37,"role":34},"Congguo Yin","Hangzhou First Hospital of Zhejiang University",{"name":39,"affiliation":40,"role":34},"Tingyu Yi","Zhangzhou Affiliated Hospital of Fujian Medical University",{"name":42,"affiliation":43,"role":34},"Chong Zheng","Longyan First Hospital of Fujian Medical University",{"name":45,"affiliation":46,"role":34},"Chenghua Xu","Taizhou First People's Hospital",{"name":48,"affiliation":49,"role":34},"Zhongfan Ruan","The First Affiliated Hospital, Hengyang Medical School, University of South China",[51,55],{"name":48,"role":52,"phone":53,"phoneExt":25,"email":54},"CONTACT","15616320002","ruanzhongfan@sina.com",{"name":56,"role":52,"phone":57,"phoneExt":25,"email":58},"Zhongming Qiu","13236599269","qiuzhongmingdoctor@163.com",[60,74],{"facility":49,"status":61,"city":62,"state":63,"zip":25,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"RECRUITING","Hengyang","Hunan","China","CN",{"type":67,"coordinates":68},"Point",[69,70],112.61888,26.88946,{"lat":70,"lon":69},[73],{"name":48,"role":52,"phone":25,"phoneExt":25,"email":54},{"facility":33,"status":61,"city":75,"state":63,"zip":76,"country":64,"countryCode":65,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Xiangtan","421001",{"type":67,"coordinates":78},[79,80],112.9,27.85,{"lat":80,"lon":79},[83],{"name":32,"role":52,"phone":84,"phoneExt":25,"email":85},"18973223018","yuanguangxiong74@163.com",{"type":87,"investigatorFullName":56,"investigatorTitle":88,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Professor",[90,92,93,96,98,99],{"name":91,"class":6},"The First Affiliated Hospital of University of South China",{"name":33,"class":6},{"name":94,"class":95},"Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University","UNKNOWN",{"name":97,"class":95},"Longyan First Affiliated Hospital of Fujian Medical University",{"name":46,"class":6},{"name":40,"class":6},"100545916","endovascular-treatment-for-extra-large-ischemic-stroke-100545916",false,"NCT06388148","Endovascular Treatment for eXtra-Large Ischemic Stroke","Efficacy and Safety of Endovascular Thrombectomy Plus Medical Management Versus Medical Management Alone in Acute Ischemic Stroke Patients With Large Vessel Occlusion and Extra-Large Infarct Core: A Multicenter, Randomized Controlled Trial","XL STROKE-2","Inclusion Criteria:\n\n1. Age 18 years or older, and modified Rankin scale score = 0 or 1 in patients 80 years or older;\n2. Acute ischemic stroke within 6 hours from last known well to randomization, or with negative MRI-FLAIR (no change on FLAIR sequence and presence of infarct on MRI-DWI) if \\> 6 hours or unknown last known well time;\n3. Occlusion of the internal carotid artery, M1 or M2 segment of the middle cerebral artery confirmed by CTA\u002FMRA\u002FDSA;\n4. Baseline ASPECTS score of 0-2 or infarct core volume ≥100ml;\n5. The patient or patient's representative signs a written informed consent form.\n\nExclusion Criteria:\n\n1. CT or MR evidence of hemorrhage;\n2. Evidence of mass effect with ventricular effacement, midline shift or herniation on baseline imaging;\n3. Vessel tortuosity where it is expected that the thrombectomy device will not be able to reach the occlusion site or result in unstable access;\n4. History of bleeding disorders, severe heart, liver or kidney disease, or sepsis;\n5. Currently participating in another investigational drug study;\n6. Any terminal illness with life expectancy less than 6 months.","ALL","18 Years",{"count":111,"type":112},286,"ESTIMATED","INTERVENTIONAL",[115],"NA","The role of endovascular thrombectomy in patients with extra-large ischemic burden is still unclear. The XL STROKE-2 randomized trial is aiming to investigate the efficacy and safety of mechanical thrombectomy in acute extra-large ischemic stroke patients with large vessel occlusion.",[118],"Stroke, Acute Ischemic","2025-12-18",{"date":121,"type":122},"2025-12-26","ACTUAL",{"date":124,"type":122},"2024-06-16",{"date":126,"type":112},"2027-01-31",{"name":56,"class":6},2]